The National Institute of Health's COVID-19 Treatment Guidelines Panel recommends against the use of Janus kinase (JAK) inhibitors such as baricitinib, ruxolitinib, and tofacitinib for the treatment of COVID-19, except in a clinical trial. 
The Infectious Diseases Society of America COVID-19 Guidelines do not mention the use of ruxolitinib or other JAK inhibitors for COVID-19. 
The Centers for Disease Control and Prevention does not provide any specifics on the use of JAK inhibitors for COVID-19. 
A review article assessing the role of ruxolitinib in the inhibition of cytokine signaling and associated implications for COVID-19 stated that early clinical findings support expedited investigation of ruxolitinib in phase 3 clinical trials. Ruxolitinib at pharmacologically achievable doses may be able to mitigate the hyperinflammatory state observed in patients experiencing COVID-19–associated cytokine storm. 
A review assessed role of specific and non-specific immunomodulating agents, including neutralizing monoclonal antibodies, corticosteroids, and other molecules in the management of severe COVID-19, along with the impact of these agents on survival and clinical symptoms. The role and safety of a JAK inhibitor in the management of inflammatory cytokine storm caused by COVID-19 is questionable. The review included a study in which two patients had to discontinue ruxolitinib treatment. The patients developed cutaneous reactions with purpuras and a progressive decrease in hematocrit values, and one patient also developed thrombocytopenia and a deep-tissue infection. 
A review article assessing the potential efficacy of ruxolitinib in COVID-19 hypothesized that since ruxolitinib is well-tolerated and used in the elderly population, it is a powerful candidate to overcome the hyperimmune syndrome that arises in COVID-19 patients. Ruxolitinib reduced the expression of inflammatory biomarkers at both the gene and protein levels in different cells. The authors concluded that ruxolitinib has potential in the treatment of COVID-19 infection; however, adverse effects such as opportunistic infections must also be considered. 
An review assessing different treatment options for COVID-19 stated that there is possible use of ruxolitinib as an IL-6 inhibitor in the advanced stages of the infection.